To view this email as a web page, click here.

In this issue of Dermatology Times, we explore new drugs on the horizon for basal cell carcinoma and melanoma, advances in acne and psoriasis, and the latest in neurotoxin news. We also brief you on coding changes and offer tips to help you survive a practice audit. Discover these and other topics online from this month's issue.
 
Dermatology Times cover
Dermatology Times cover
Basal cell carcinoma treatments on the horizon
In this pipeline report, we present insights into two drugs currently in phase 2 and phase 3 for the treatment of basal cell carcinoma.

What's new in melanoma treatment?
Innovative melanoma therapeutics are on the horizon. This pipeline report highlights some of the new drugs currently in phase 2, phase 3 or recently approved for the treatment of melanoma.

Medical billing and coding changes you should know
Coding is a major determinant of what dermatologists bill and what they get paid, so it’s critical to keep up with changes to be both compliant and accurate. Mollie MacCormack, M.D., and Murad Alam, M.D. demystify coding conundrums in this article.

Tips to minimize audit stress
Audits can be an unfortunate reality of practicing medicine. This expert explains the four main types of audits and offers tips to minimize audit stress.

Table: Product ingredient list
This table includes an easy-to-reference list of active acne ingredients and skin protectant ingredients allowable in over-the-counter products.
 
Connect with us on Twitter and Facebook for daily updates.
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.